Hepa-Merz (Ornithine Aspartate)

Hepa-Merz is used in clinical settings to manage conditions associated with elevated ammonia levels and impaired liver function.

• Treatment of hepatic encephalopathy in patients with acute or chronic liver disease.
• Adjunct therapy for liver cirrhosis to improve metabolic balance.
• Management of hyperammonemia resulting from urea‑cycle disorders.
• Supportive care during acute decompensation of liver disease.
• Used as part of a comprehensive regimen for patients awaiting liver transplantation.

Side effects of Hepa-Merz vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

• Mild nausea or vomiting.
• Transient headache.
• Slight increase in serum bilirubin.
• Temporary dizziness.
• Local irritation at the infusion site.
• Mild electrolyte imbalance.

Serious

• Severe allergic reaction (anaphylaxis).
• Acute hypotension or shock.
• Significant hepatic decompensation.
• Persistent vomiting leading to dehydration.
• Cardiac arrhythmia.
• Renal impairment secondary to high ammonia levels.

When prescribing Hepa-Merz, clinicians should consider several precautionary measures to ensure patient safety.

• Verify liver function tests and ammonia levels before initiation.
• Use only under supervision of a qualified healthcare professional.
• Adjust infusion rate in patients with cardiovascular instability.
• Monitor for signs of hypersensitivity during the first administration.
• Caution in patients with renal insufficiency; assess renal function regularly.
• Avoid use in pregnant or breastfeeding women unless clearly indicated.
• Discontinue if severe adverse reactions occur.

Hepa-Merz may interact with other medications that affect ammonia metabolism or cardiovascular stability.

Avoid

• Concurrent use of high‑dose lactulose that may exacerbate electrolyte shifts.
• Co‑administration with potent vasodilators that could worsen hypotension.
• Simultaneous infusion of other nephrotoxic agents.

Use with caution

• Benzodiazepines, as altered hepatic function may increase sedation.
• Diuretics, due to potential electrolyte disturbances.
• Anticoagulants, because of possible changes in plasma protein binding.